AlphaHelix Molecular Diagnostics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, sales was SEK 24.37 million compared to SEK 31.91 million a year ago. Revenue was SEK 24.65 million compared to SEK 32.55 million a year ago. Net loss was SEK 2.19 million compared to net income of SEK 5.04 million a year ago. Basic loss per share from continuing operations was SEK 0.03 compared to basic earnings per share from continuing operations of SEK 0.08 a year ago.